Kiniksa Pharmaceuticals International (KNSA) Return on Capital Employed (2018 - 2026)

Kiniksa Pharmaceuticals International has reported Return on Capital Employed for 9 years, with the latest figure at 6.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 921.0% year-over-year to 6.01%; the trailing twelve-month figure through Mar 2026 stood at 6.01% (up 921.0% YoY), and the FY2025 full-year result was 4.19%, up 1426.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 6.01%, up from 3.73% in the prior quarter.
• The five-year high for Return on Capital Employed was 9.16% in Q2 2023, with the low at 71.98% in Q1 2022.
• Historically, Return on Capital Employed has averaged 9.0% across 5 years, with a median of 4.47% in 2023.
• Annual changes were most pronounced in 2022 — Return on Capital Employed jumped 10835 bps — and 2024, when it plunged 1531 bps.
• Kiniksa Pharmaceuticals International's Return on Capital Employed stood at 2.37% in 2022, then slumped by 341 bps to 5.71% in 2023, then sank by 71 bps to 9.76% in 2024, then jumped by 138 bps to 3.73% in 2025, then surged by 61 bps to 6.01% in 2026.
• The last three Return on Capital Employed figures came in at 6.01% (Q1 2026), 3.73% (Q4 2025), and 6.78% (Q3 2025), per Business Quant data.